Alx oncology to present new evorpacept clinical data in myelodysplastic syndromes at 63rd ash annual meeting

South san francisco, calif., nov. 04, 2021 (globe newswire) -- alx oncology holdings inc., (“alx oncology”) (nasdaq: alxo), a clinical-stage immuno-oncology company developing therapies to block the cd47 checkpoint pathway, today announced the company will be presenting early clinical data from aspen-02, its ongoing phase 1/2 study evaluating evorpacept in combination with azacitidine for the treatment of myelodysplastic syndromes (“mds”) in a poster presentation at the 63rd american society of hematology (“ash”) annual meeting held december 11-14, 2021 in atlanta, georgia.
ALXO Ratings Summary
ALXO Quant Ranking